Polycystic Ovary Syndrome Treatment Market Opportunity Analysis-2027


Posted March 8, 2021 by SANJAYCMI

“Coherent Market Insights “POLYCYSTIC OVARY SYNDROME TREATMENT MARKET – GLOBAL TRENDS, ESTIMATES AND FORECASTS, 2020-2027″
 
There are four types of polycystic ovary syndrome: Insulin-resistant polycystic ovary syndrome, inflammatory polycystic ovary syndrome, hidden-cause polycystic ovary syndrome, and pill-induced polycystic ovary syndrome.

Statistics:

The global Polycystic Ovary Syndrome Treatment Market is estimated to account for US$ 945.1 Mn in terms of value and is expected to reach US$ 1,311.0 Mn by the end of 2027.

Global Polycystic Ovary Syndrome Treatment Market: Drivers

Increasing funding for R&D is expected to propel growth of the global polycystic ovary syndrome treatment market over the forecast period. For instance, in 2019, Wellcome Trust funded a US$ 3 million project that observed 1,000 women suffering from polycystic ovary syndrome in three studies including the testing of a new drug.

Global Polycystic Ovary Syndrome Treatment Market: Opportunities

Launch of branded products as a direct treatment for polycystic ovary syndrome is expected to offer lucrative growth opportunities for players in the global polycystic ovary syndrome treatment market. Currently, there are no drugs approved by FDA and EMA for the treatment of polycystic ovary syndrome. Thus, drug manufacturers are being presented the opportunity to hold significant share in the market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1589

Global Polycystic Ovary Syndrome Treatment Market: Restraints

Lower diagnosis rate in underdeveloped economies is expected to hinder growth of the global polycystic ovary syndrome treatment market. Awareness regarding polycystic ovary syndrome and its symptoms among populations in underdeveloped economies is significantly low.

Key Takeaways:

The global polycystic ovary syndrome treatment market was valued at US$ 904.7 Mn in 2019 and is forecast to reach a value of US$ 1,311.0 Mn by 2027 at a CAGR of 4.8% between 2020 and 2027. Major factor driving the growth of global polycystic ovary syndrome treatment market during the forecast period include high prevalence of polycystic ovary syndrome, and research and development.

Insulin Sensitizing Agents held dominant position in the global polycystic ovary syndrome treatment market in 2019, accounting for 32.9% share in terms of value, followed by Aromatase Inhibitors & SERMs and Oral contraceptives, respectively.

Market Trends

Increasing awareness regarding polycystic ovary syndrome is expected to propel growth of the global polycystic ovary syndrome treatment market. For instance, in September 2019, SIHF Healthcare, U.S. raised awareness of polycystic ovary syndrome on the occasion of Polycystic Ovary Syndrome (PCOS) Awareness Month.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/polycystic-ovarian-syndrome-treatment-market-1589

Moreover, R&D in polycystic ovary syndrome is also expected to aid in growth of the market. For instance, in 2018, an international consortium, including researchers at the Icahn School of Medicine at Mount Sinai, conducted a whole genome association study to identify common genetic architecture for different diagnostic criteria used to define polycystic ovary syndrome.

Global Polycystic Ovary Syndrome Treatment Market: Competitive Landscape

Major players operating in the global polycystic ovary syndrome treatment market include, Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., and Crinetics Pharmaceuticals, Inc.

Global Polycystic Ovary Syndrome Treatment Market: Key Developments

Major players in the global polycystic ovary syndrome treatment market are focused on adopting M&A strategies to expand their product portfolio. For instance, in August 2020, Bayer AG acquired U.K.-based KaNDy Therapeutics and its investigational treatment for menopause with a US$ 425 million upfront payment, in order to expand its women’s healthcare pipeline.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1589

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Coherent Market Insights
Phone +1-206-701-6702
Business Address 1001 4th Ave
# 3200 Seattle, WA 98154, U.S.
Country United States
Categories Health , Marketing , Research
Tags polycystic ovary syndrome treatment , polycystic ovary syndrome treatment market analysis , polycystic ovary syndrome treatment market outlook
Last Updated March 8, 2021